

REAL-WORLD SURVIVAL AND COST ANALYSIS OF ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS: A MULTICENTRE RETROSPECTIVE STUDY

4CPS-277

T. GARCIA¹, G. GONZÁLEZ MORCILLO², M. ZAFORTEZA DEZCALLAR², V. CARRILLO LÓPEZ², C. MARTORELL PUIGSERVER¹, J. GARCÍA-CALVO NAVARRO³, R.A. FREITES NAVA¹, M. CABALLERO SÁNCHEZ⁴, D. GALINDO SAN SEGUNDO¹, M. AGUASCA ADROVER¹, H. PADILLA CASTAÑO¹

¹SON ESPASES UNIVERSITY HOSPITAL, ²CENTRAL PHARMACY SERVICES, ³MATEU ORFILA HOSPITAL, ⁴SON LLATZER UNIVERSITARY HOSPITAL BALEARIC ISLAND, SPAIN

BACKGROUND AND IMPORTANCE

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease. with a median survival of 2–5 years from symptom onset. Antifibrotic agents—nintedanib and pirfenidone—slow disease progression and may extend survival.




PIRFENIDONE
NINTEDANIB

However, real-world data on survival outcomes between both treatments and treatment costs remain limited.

AIM AND OBJECTIVES

To compare overall survival (OS) in patients with IPF treated with nintedanib versus pirfenidone, and to assess associated treatment costs.

MATERIAL AND METHODS



EFFECTIVENESS ANALYSIS

OVERALL SURVIVAL (OS)
Kaplan Meier method and log-rank test



ECONOMIC ANALYSIS

- 1 THEORETICAL ANNUAL TREATMENT COST (ATC) NHS 2018-2022
- 2 REAL-WORLD MEAN ANNUAL COST PER PATIENT


RESULTS

244 PATIENTS INCLUDED
≥18 years
FPI diagnosed and treated with nintedanib or pirfenidone between January 2016 and December 2024

37 PATIENTS EXCLUDED
both antifibrotic drug used
CROSS-OVER BIAS

207 PATIENTS FOR OS ANALYSIS

EFFECTIVENESS ANALYSIS




Age bias factor:

PIRFENIDONE
70,5 years
VS
NINTEDANIB
66,4 years
P=0,0003


ECONOMIC ANALYSIS

1 THEORETICAL ANNUAL TREATMENT COST (ATC)



2 REAL-WORLD MEAN ANNUAL COST PER PATIENT

	LABEL COST (IQR)	MEAN ANNUAL COST (SD)
NINTEDANIB	7.009,34 € - 17.196,12€	12.505,12 € (3.050,84 €)
PIRFENIDONE (2016-2023)	5.740,98 € - 17.222,93€	11.723,47 € (5.871,28 €)
PIRFENIDONE GENERIC (2023-2024)	206,88€ - 930,69€	902,22 € (237,37 €)



48.2% POST-GENERIC

CONCLUSIONS

Although not statistically significant, a survival trend favouring nintedanib was observed.

Generic pirfenidone substantially reduced treatment costs, supporting its value in reducing the economic burden of IPF

